

VIRTUAL GULF ADVISORY BOARD

JOIN MEETING

MODERATOR



Dr. Murtadha Al Khabori

Dr. Murtadha Al Khabsi
Consultant Hematologist at Sultan Qaboos University Hospital

INVITED INTERNATIONAL EXPERT



Dr. Mark Litzow

Professor of Medicine in the Division of Hematology at Mayo Clinic.
He Was the Director of the BMT Program at Mayo from 1992 to 2008

ALL ADVISORS*



Dr. Mahmoud Marashi

Consultant Hematologist at Mediclinic
City Hospital / Dubai Hospital



Dr. Faraz Khan

Consultant Hematologist and
Medical Oncologist, American
Hospital, Dubai, UAE



Dr. Ahmed Al Huraiji

Consultant Hematologist at
Kuwait Cancer Control Center



Dr. Hasan Al Yaseen

Consultant Hematologist at
Dubai Hospital



Dr. Arif Alam

Consultant Hematologist at
Tawam Hospital



Dr. Ruba Taha

Consultant Hematologist at
National Center for Cancer Care
& Research



Dr. Murtadha Al Khabori

Dr. Murtadha Al Khabor
Consultant Hematologist at Sultan
Qaboos University Hospital

AGENDA

TIME	SESSION	SPEAKER	MODERATOR
	Introduction & Welcome	Amgen Team	Dr. Murtadha Al Khabori
05:30 – 05:40 pm	Current Treatment Paradigms in Gulf in Ph- B-ALL Pre ad board survey Qs related to E1910	Dr. Murtadha Al Khabori	
05:40 – 06:00 pm	Deep Dive into E1910 -Dr. Mark Litzow presentation -The rationale for this chemo backbone selection -Rational for transplant selection, is there a risk stratification sub analysis? Wide age group selection? MRD-ve detection and Rx decision? -Explain study outcomes: OS, 41% drop out rates? Subgroup analysis for age and no. of Blin cycles	Dr. Mark Litzow	
06:00 – 06:30 pm	Discussion Points -What is your perception on the OS as a primary endpoint outcomes in MRD negative patients? -Do you anticipate any changes in the MRD determination based on the available data? - What are your thoughts on the outcomes of the chemotherapy regimen (modified E2993/UKALLXII) used in this trial compared to your SOC?	ALL Advisors + Dr. Mark Litzow	
06:30 – 07:50 pm	Similarities and Difference in Chemotherapy Backbone Workshop - What is your perception of E1910 chemotherapy backbone compared to HCVAD+INO+Blin? - What about the UKALL protocols (would you say it is more or less intense? And why? - Which consolidation modality would you prefer? A. Full CT blocks + 4 Blin sequentially B. Reduced CT blocks + 4 Blin sequentially C. Chemo-free Blin based consolidation	Dr. Hasan Al Yaseen (10 min)	
	E1910 Data Discussion Study Implementation - What impact will the concept of the E1910 study have on your treatment practice? - Can the data be extrapolated to other chemo backbones? - Would you consider Blin as consolidation in 1L regardless of MRD status? If yes, how many cycles of Blin would you use? - Which specific subgroups do you think would benefit most/least from this treatment approach and why? • Can the E1910 data be extrapolated to patients younger than age 30 in clinical practice? Why or why not? • Would you consider re-treatment with Blin at MRD+? If not, what would be your preferred options at MRD+?	ALL Advisors + Dr. Mark Litzow	Dr. Murtadha Al Khabori
07:50 – 08:00 pm	Closing Remarks QR code: What final recommendation for Amgen launching E1910 study in your country?	Amgen Team	

This is an individual invitation